Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

NCT00239291 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Metastatic Prostate Cancer

Interventions

DRUG: Gefitinib, radiotherapy

Sponsor

AstraZeneca